Literature DB >> 6201807

Synovial sarcoma: an Australian series of 48 cases.

R A Zito.   

Abstract

A series of 48 cases of synovial sarcomas submitted to the Australasian Soft Tissue Tumour Registry between 1965 and 1980 is reported. Tumours were analysed with regard to clinical features, morphology and outcome. The overall 5-yr survival rate for all assessable cases was 50%. A strong relationship between size and survival was noted with a 73% 5-yr survival rate where tumours were less than 5 cm in maximum diameter. Biphasic tumours (16 cases) appeared to have a better prognosis, with a mean survival time of 6.1 yr as compared with 4 yr for monophasic tumours (32 cases); however, the former were generally slightly smaller tumours. Tumours with less than 5 mitoses per 10 highpower fields (2.8 sq mm) had double the mean survival time of other tumours. The histological features of swirling architecture, monotonous cell type, vascular pattern, myxoid foci, collagen production, mast cell presence and calcification are recommended as cumulative factors in arriving at a diagnosis where a biphasic pattern is not apparent.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6201807     DOI: 10.3109/00313028409067910

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  3 in total

1.  Synovial sarcoma: a clinicopathological review.

Authors:  S A Henderson; R Davis; J R Nixon
Journal:  Int Orthop       Date:  1991       Impact factor: 3.075

Review 2.  Of mice and men: opportunities to use genetically engineered mouse models of synovial sarcoma for preclinical cancer therapeutic evaluation.

Authors:  Kevin B Jones; Malay Haldar; Joshua D Schiffman; Lisa Cannon-Albright; Stephen L Lessnick; Sunil Sharma; Mario R Capecchi; R Lor Randall
Journal:  Cancer Control       Date:  2011-07       Impact factor: 3.302

3.  Synovial sarcoma. A clinicopathological study of 31 cases.

Authors:  S Santavirta
Journal:  Arch Orthop Trauma Surg       Date:  1992       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.